Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 202. Ovbiagele B. Low-normal systolic blood pressure and second- ary stroke risk. J Stroke Cerebrovasc Dis. 2013;22:633 638. doi: 203. Lin MP, Ovbiagele B, Markovic D, Towfighi A. Systolic blood pressure and mortality after stroke: too low, no go? Stroke. 2015;46:1307 1313. doi: 204. Kim J, Gall SL, Nelson MR, Sharman JE, Thrift AG. Lower systolic blood pressure is associated with poorer survival in long-term survivors of stroke. J 205. Sandset EC, Bath PM, Boysen G, Jatuzis D, K rv J, L ders S, Murray GD, Richter PS, Roine RO, Ter nt A, et al; SCAST Study Group. The angioten- sin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377:741 206. PATS Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. Chinese Med J. 1995;108:710 717. 207. Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, Silani V, Bilo G, Corrao G, Zambon A, et al. Blood pressure and LDL- cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens. 2014;32:1888 1897. 208. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic at- tack. N Engl J Med. 2006;355:549 559. doi: 10.1056/NEJMoa061894 209. Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, et al; SPARCL Investigators. 